SCHEMBL20135320

SCHEMBL20135320

COCC(C)(C)C1(c2ccc(C(=O)O)cc2)NC(=O)NC1=O

nearest known ligand 0.34

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34
MMP9 P14780 5/20 0.34
MMP2 P08253 4/20 0.34
MMP8 P22894 4/20 0.34
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
MMP3 P08254 1/20 0.33
MMP13 P45452 1/20 0.33
RXRA P19793 2/20 0.32
RXRB P28702 2/20 0.32
RXRG P48443 1/20 0.32
SRD5A2 P31213 1/20 0.32
NR4A2 P43354 1/20 0.32
ALDH1A1 P00352 2/20 0.31
METAP1 P53582 1/20 0.31
AKR1B1 P15121 1/20 0.31
HCAR3 P49019 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20134906 0.83 CA1 (0.37) CA1CA2MMP9MMP2MMP8
SCHEMBL20134813 0.82 RXRA (0.38) MMP9MMP2MMP8MMP3MMP13
SCHEMBL20135162 0.76 SRD5A2 (0.38) CA1CA2MMP9MMP2MMP8
SCHEMBL20134952 0.73 ADAM17 (0.42) CA1CA2MMP9MMP2MMP8
SCHEMBL20134924 0.71 ADAMTS5 (0.40) MMP2MMP13
SCHEMBL20791718 0.69 HCAR3 (0.42) CA1CA2MMP9MMP2MMP8
SCHEMBL20135039 0.69 ADAM17 (0.39) MMP2MMP13
SCHEMBL20134880 0.68 MEN1 (0.55) MMP9MMP2MEN1KMT2ARXRA
SCHEMBL4308515 0.68 MEN1 (0.55) MMP9MMP2MEN1KMT2ARXRA
SCHEMBL20134968 0.68 CA12 (0.47) CA1CA2RXRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107922347-B Novel imide derivatives and their use as pharmaceuticals 田边三菱制药株式会社 2022-06-28 CN disclosed
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 US disclosed
US-10407408-B2 Imide derivatives and use thereof as medicine MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-09-10 US disclosed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 US disclosed
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2019-03-14 US disclosed
EP-3321256-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE Mitsubishi Tanabe Pharma Corporation (JP) 2018-05-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190077787-A1 NOVEL IMIDE DERIVATIVES AND USE THEREOF AS MEDICINE MMP9, MMP10, MMP1 CA1 1423/4885CA2 579/4885MMP9 1/4885
US-10407408-B2 Imide derivatives and use thereof as medicine MMP9, MMP2, MMP1 CA1 1245/4885CA2 470/4885MMP9 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.